10x Genomics, Inc. — Director's Dealing 2021

Dec 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2021-12-07

Reporting Person: Saxonov Serge (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-07	Class A Common Stock	M	5209	$5.04	Acquired	889818	Direct
2021-12-07	Class A Common Stock	M	3037	$11.48	Acquired	892855	Direct
2021-12-07	Class A Common Stock	S	200	$138.8600	Disposed	892655	Direct
2021-12-07	Class A Common Stock	S	766	$142.3954	Disposed	891889	Direct
2021-12-07	Class A Common Stock	S	3187	$143.3578	Disposed	888702	Direct
2021-12-07	Class A Common Stock	S	672	$144.2703	Disposed	888030	Direct
2021-12-07	Class A Common Stock	S	571	$145.7923	Disposed	887459	Direct
2021-12-07	Class A Common Stock	S	6480	$147.0497	Disposed	880979	Direct
2021-12-07	Class A Common Stock	S	2370	$147.9635	Disposed	878609	Direct
2021-12-07	Class A Common Stock	S	754	$148.5982	Disposed	877855	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-07	Stock Option (right to buy)	$5.04	M	5209	Disposed	2028-11-02	Class A Common Stock (5209)	Direct
2021-12-07	Stock Option (right to buy)	$11.48	M	3037	Disposed	2029-05-10	Class A Common Stock (3037)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Class A Common Stock	4498	Indirect
Class A Common Stock	89960	Indirect

Footnotes

F1: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2: This transaction was executed in multiple trades at prices ranging from $141.77 to $142.59. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3: This transaction was executed in multiple trades at prices ranging from $142.86 to $143.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F4: This transaction was executed in multiple trades at prices ranging from $144.00 to $144.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F5: This transaction was executed in multiple trades at prices ranging from $145.34 to $146.33. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F6: This transaction was executed in multiple trades at prices ranging from $146.45 to $147.42. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F7: This transaction was executed in multiple trades at prices ranging from $147.4621 to $148.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F8: This transaction was executed in multiple trades at prices ranging from $148.545 to $148.74. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F9: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.

F10: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

F11: This option, originally for 250,000 shares, of which 196,677 have been exercised, vested as to 1/48th of the shares on October 1, 2018, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F12: This option, originally for 145,786 shares, of which 97,190 have been exercised, vested as to 1/48th of the shares on May 1, 2019, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.